Idealhalers or realhalers? A comparison of Diskus and Turbuhaler

International Journal of Clinical Practice

Volumn 59, Issue 12, 2005, Pages 1488-1495

  Borgström, Lars ^a   Asking, L ^a   Thorsson, L ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; COPD; Diskus ; Lung deposition; Turbuhaler

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE; TERBUTALINE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT;

ASTHMA; CLINICAL TRIAL; DEVICE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; EQUIPMENT DESIGN; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; HUMIDITY; INHALER; INTERMETHOD COMPARISON; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; STANDARD;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33646843049     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00747.x     Document Type: Review

References (34)

1. Busse W. Dose-related efficacy of Pulmicort ® (BUD) Turbuhaler ® in moderate to severe asthma. J Allergy Clin Immunol 1994; 93 (Suppl. 1 Pt 2): 186.
2. Dahl R, Lundback B, Malo J et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-8.
3. Szefler S, Martin R, King T et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-8.
4. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-40.
5. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52: 1-34.
6. Kraan J, Koeter G, van der Mark T et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44-8.
7. Van Essen-Zandvliet E, Hughes M, Waalkens H et al. Effects of 22 months' treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547-54.
8. Beasley R, Sterk P, Kerstjens H, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J 2001: 579 -80.
9. Backman R, Baumgarten C, Sharma R. Fluticasone propionate via Diskus(TM) inhaler at half the microgram dose of budesonide via Turbuhaler(TM) inhaler. Clin Drug Invest 2001; 21: 735-43.
10. Manjra A, Versteegh F, Mehra S, Zhang P, Mark S. Clinical equivalence of fluticasone propionate (FP) 400 mcg daily via the Diskus inhaler and budesonide (B) 800 mg daily via the Turbuhaler in asthmatic children. Eur Respir J 1998; 12 (Suppl. 28): 87S.
11. Kuna P. A randomized, double-blind, double-dummy, parallell-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone drypowder inhalers in adults with mild to moderate asthma. Clin Ther 2003; 25: 2182-97.
12. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997; 99: 773-80.
13. Thorsson L, Edsbäcker S, Källén A, Löfdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus ® and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529-38.
14. Borgström L, Bisgaard H, O'Callaghan, C, Pederson S. Dry-powder inhalers. In: Bisgaard H, O'Callaghan C, Smaldone G, eds. Drug Delivery to the Lungs. New York: Marcel Dekker Inc., 2002: 421-48.
15. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler in children. Am J Respir Crit Care Med 2003; 168: 779-82.
16. Asking L, Lööf T, Pettersson G. Flutide Diskus less consistent than Pulmicort Turbuhaler with respect to in vitro fine particle dose proportionality. Am J Respir Crit Care Med [Accepted].
17. Pauwels R, Newman S, Borgstor̈m L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997; 10: 2127-38.
18. Bisgaard H, Klug B, Burnell PK, Sumby B. Use of inhalation profiles from paediatric asthmatics using the Diskus and Turbuhaler inhalers to evaluate product performance in-vitro. Am J Respir Crit Care Med 1996; 153: A75.
19. Gustafsson P, Andersson H, Glad M, Johal B, Burnell PKP. Comparison of total and fine drug particle mass generated from two dry powder inhalers (DPIs) by 4-year old children with asthma. Eur Respir J 2002; 20: 429s.
20. Olsson B, Borgström L, Asking L, Bondesson E. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press Inc, 1996: 273-81.
21. Bisgaard H, Klug B, Sumby B, Burnell P. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11: 1111-5.
22. Borgström L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001; 14: 281-7.
23. Meijer R, van der Mark T, Aalders B, Postma D, Koëter G. Home assessment of peak inspiratory flow through the Turbuhaler in asthmatic patients. Thorax 1996; 51: 433-4.
24. Pedersen S, Hansen O, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308-10.
25. Lipniunas P, Westfal J, Asking L. Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products. Eur Respir J 2002; 20: 541s.
26. Shaw M. Effective and reliable drug delivery. Turbuhaler. Oxford, UK: Clinical Vision Ltd, 1999.
27. Lipniunas P, Asking L. An in-vitro comparison of two dry powder inhalers after storage at hot and humid conditions. Am J Respir Crit Care Med 2003; 167 (Suppl.): A896.
28. Borgström L, Lipniunas P. Symbicort (R) Turbuhaler (R) is not affected by storage at hot and humid conditions. A clinical pharmacokinetic comparison with Seretide (TM) Diskus (TM). Am J Respir Crit Care0 Med 2003; 167 (Suppl.): A896.
29. Asking L, Axelsson M, Lindberg J. Aluminium blisters may fail to protect against humidity. In: Drug Delivery to the Lungs IX. London, UK 1998: 84-7.
30. Jashnani R, Byron P, Dalby R. Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharm 1995; 113: 123-30.
31. Lindsay D, Russell N, Thompson J, Warnock T, Shellshear I, Buchanan P. A multicentre comparison of the efficacy of terbutaline Turbuhaler ® and salbutamol pressurized metered dose inhaler in hot, humid regions. Eur Respir J 1994; 7: 342-5.
32. Nana A, Youngchaiyud P, Maranetra N et al. ß 2 -agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92: 167-72.
33. Finlay W, Zhang M, Grgic B et al. Solving a major in vitro-in vivo correlation problem: Impaction induction ports. In: Dalby N, Byron P, Peart J, Suman J, Farr S, eds. Respiratory Drug Delivery IX. Palm Desert, CA, USA: Davis Healthcare International Publishing, LCC, 2004: 203-10.
34. Thorsson L, Edsbäcker S. Less variability in lung deposition of budesonide via Turbuhaler than of fluticasone via Diskus/Accuhaler and pMDI in adults. Am J Respir Crit Care Med 2003; 167: A896.